CClinicalTrials.gg
Status unknownNCT03479359Updated Mar 27, 2018

Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship

An observational study in Prostatic Neoplasms, Digital Rectal Examination and Benign Prostatic Hyperplasia, sponsored by Changhai Hospital. Status unknown at 1 site in China. Open to male participants. Per ClinicalTrials.gov, last updated 2018-03-27.

Sponsored by Changhai Hospital · Observational

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
700
Sex
Male
01

Study summary

The investigators conduct this prospective study to investigate the learning curve of digital rectal examination (DRE) for prostate cancer among internship. The investigators want to know how many DRE are usually needed for internship to be performed in urological practice to obtain a stable DRE accuracy.

Read the detailed description

Digital rectal examination (DRE) is a basic physical examination in routine practice in Urology. The DRE is a very important daily practice for screen prostate cancer, and each internship in Urology is required to perform this for patients suspected of prostate cancer or benign prostate hyperplasia. However, how many DRE are usually needed for a internship to perform so as to obtain a stable accuracy in daily practice is currently unknown. The investigators thus conduct this prospective trial to investigate the learning curve of DRE among internship.

02

Conditions studied

  • Prostatic Neoplasms
  • Digital Rectal Examination
  • Benign Prostatic Hyperplasia

Keywords

  • Prostate cancer; Benign Prostatic Hyperplasia; Digital Rectal Examination; Accuracy
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All included internship are graduated from the Second Military Medical University and have already get the M.D. degree

Inclusion criteria

  • Internship just graduate from the medical school, and agree to attend the study.
  • Internship have less than 5 DREs of prostate cancer.
  • Patients of any age who are included for prostate biopsy are eligible, the indications for prostate biopsy are as follows: PSA>4ng/ml, fPSA/tPSA\<0.16, with suspected palpable nodes in the prostate by DRE of attending doctor, suspected mass in prostate detected by ultrasound examination, magnetic resonance imaging, or computed tomography.

Exclusion criteria

Exclusion Criteria:

  • Internship who are not willing to attend the study.
  • Internship stop doing DRE for continuously 3 months after entering the study.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1

    In this group, internship are given the pathology outcome of each prostate biopsy regularly twice a month.

    Behavioral: Routine review of DRE results by attending doctors

  • Group 2

    In this group, internship are not given the pathology outcome of each prostate biopsy.

Interventions

  • BehavioralRoutine review of DRE results by attending doctors

    Let the internship regularly compare DRE result and the pathology outcome of prostate biopsy of each patient.

05

What researchers measure

Primary outcomes

  1. Sensitivity and specificity of DRE performed by internship will be confirmed by prostate biopsy

    To examine the sensitivity and specificity of the DRE performed by internship to reference standard of prostate biopsy in a prospective longitudinal cohort of around 700 participants who will undergo prostate biopsy due to suspect of prostate cancer. The investigators will investigate the sensitivity and specificity of DRE by different internship monthly.

    Time frame: One year

Secondary outcomes

  1. Sensitivity and specificity of DRE performed by internship with different training plan will be confirmed by prostate biopsy

    To examine the sensitivity and specificity of the DRE performed by internship (group 1 with routinely review of pathologic outcome of prostate biopsy twice a month, and group 2 internship who are not told the results of prostate biopsy) to standard reference of prostate biopsy.

    Time frame: One year

  2. Sensitivity and specificity of DRE performed by internship will be compared to the results of fPSA/tPSA and MRI.

    To compare the sensitivity and specificity of DRE to fPSA/tPSA and MRI (not any patients are required to have MRI examination of prostate, this will be determined at the discretion of attending doctor) to reference standard of prostate biopsy.

    Time frame: One year

06

Study locations

1 of 1 sites recruiting
  • Changhai Hospital
    Shanghai, Shanghai 200433, China
    Recruiting
07

References and documents

Publications

  • Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. J Urol. 2018 Apr;199(4):947-953. doi: 10.1016/j.juro.2017.10.021. Epub 2017 Oct 20. PubMed 29061540 ↗
  • Clements MB, Schmidt KM, Canfield SE, Gilbert SM, Khandelwal SR, Koontz BF, Lallas CD, Liauw S, Nguyen PL, Showalter TN, Trabulsi EJ, Cathro HP, Schenkman NS, Krupski TL. Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. J Surg Educ. 2018 Mar-Apr;75(2):434-441. doi: 10.1016/j.jsurg.2017.08.012. Epub 2017 Oct 12. PubMed 28923535 ↗

Individual participant data

Plan to share: Yes — IPD will be shared after the results of the study has been published. Related information will be given if request by email is agreed by the principle investigator.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

08

Registry details

Key details

Study ID
NCT03479359
Lead sponsor
Changhai Hospital
Responsible party
Zeng Shuxiong (Attending doctor in the Department of urology, Changhai Hospital) — Principal investigator
First posted
Mar 27, 2018
Start date
Feb 26, 2018
Primary completion
Feb 26, 2019 (estimated)
Completion
Feb 26, 2019 (estimated)
Last update
Mar 27, 2018

Study contacts

Shuxiong Zeng, M.D., Ph.D
Contact
zengshuxiong@126.com
+86 18930568759
Xiong Qiao, M.D., Ph.D
Contact
xiongqiao1990@126.com
+86 02131161725
Chuanliang Xu, M.D., Ph.D
principal investigator · Second Military Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion